Nature Medicine | Efficacy and Safety of CD38-Targeted Quadruplet Therapy in Newly Diagnosed Multiple Myeloma

This study provides key evidence for treatment strategies in multiple myeloma, supporting the use of a quadruplet regimen containing an CD38 monoclonal antibody in transplant-eligible patients to achieve deeper minimal residual disease (MRD) negativity, offering direct guidance for clinical protocol optimization.

 

Literature Overview

The article titled “Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial,” published in Nature Medicine, systematically investigates the efficacy and safety of incorporating the CD38-targeted monoclonal antibody isatuximab into the carfilzomib–lenalidomide–dexamethasone (KRd) regimen for newly diagnosed multiple myeloma (NDMM) patients eligible for transplantation. Using a randomized controlled design, the study evaluates the superiority of the quadruplet regimen Isa-KRd over the standard triplet KRd during induction and consolidation therapy, with the primary endpoint being MRD negativity rate. This trial fills an evidence gap in current guidelines regarding optimal quadruplet combinations, particularly in assessing the clinical value of CD38-targeted agents when used with different proteasome inhibitors.

Background Knowledge

Multiple myeloma is a highly heterogeneous plasma cell malignancy. Despite significant advances in treatment in recent years, high-risk patients still face challenges of early relapse and poor survival outcomes. CD38 has become a core therapeutic target in NDMM due to its highly specific expression on malignant plasma cells, enabling widespread use of CD38-targeting monoclonal antibodies such as daratumumab and isatuximab in frontline therapy. However, determining the optimal drug combinations to maximize depth of response, especially achieving MRD negativity, remains a research bottleneck. Current standard regimens are mostly based on bortezomib-lenalidomide-dexamethasone combined with CD38 monoclonal antibodies, but bortezomib is often associated with toxicities such as peripheral neuropathy, limiting its long-term use. The second-generation proteasome inhibitor carfilzomib demonstrates stronger anti-tumor activity and lower neurotoxicity, suggesting it may be better suited as a backbone agent. This study directly compares the efficacy of KRd with and without a CD38 monoclonal antibody, aiming to verify whether Isa-KRd can significantly improve MRD negativity rates without increasing toxicity, thereby offering a superior treatment pathway for high-risk patients.

 

 

Research Methods and Experiments

The study employed a multicenter, open-label, randomized controlled design, enrolling 302 transplant-eligible NDMM patients aged ≤70 years, who were randomized 1:1 to receive either Isa-KRd or KRd, followed by autologous stem cell transplantation (ASCT), consolidation, and maintenance therapy. The primary endpoint was MRD negativity rate (sensitivity 10⁻⁵) assessed by next-generation sequencing (NGS) after complete-dose consolidation post-transplant. Key experimental design elements included: using NGS as the standardized MRD detection method to ensure high sensitivity and comparability; dynamically evaluating MRD status at multiple timepoints (post-induction, post-transplant, post-consolidation); and predefined exploratory analyses in high-risk subgroups (e.g., t(11;14), high-risk cytogenetic abnormalities [HRCA]). All patients underwent ASCT, and stem cell mobilization was unaffected by Isa-KRd, indicating that this quadruplet regimen does not compromise hematopoietic stem cell functionality.

Key Conclusions and Perspectives

• The MRD negativity rate (10⁻⁵) after complete-dose consolidation post-transplant was significantly higher in the Isa-KRd group than in the KRd group (77% vs 67%, OR=1.67, P=0.049), demonstrating that adding a CD38-targeted agent significantly enhances depth of response and provides high-level evidence supporting quadruplet regimens in future studies.
• At higher sensitivity (10⁻⁶), the difference in MRD negativity rates was even more pronounced (68% vs 48%, OR=2.36, P=0.0004), suggesting that CD38-targeted therapy leads to more durable deep responses, supporting the use of 10⁻⁶ as a more sensitive efficacy endpoint in clinical trials.
• Significant differences in MRD negativity rates were already evident after induction (10⁻⁵: 46% vs 27%; 10⁻⁶: 28% vs 14%), indicating that CD38 monoclonal antibodies rapidly induce deep responses, highlighting their critical role early in treatment and justifying their inclusion in initial regimens.
• The 1-year sustained MRD negativity rate (10⁻⁶) was higher in the Isa-KRd group (52% vs 38%, P=0.012), with particularly pronounced benefits in high-risk and ultra-high-risk patients (e.g., 2+ HRCA: 62% vs 20%), suggesting that CD38-targeted quadruplet therapy can overcome adverse prognoses associated with high-risk genetics, offering new hope for these difficult-to-treat populations.
• In terms of safety, rates of grade 3–4 non-hematologic toxicities, treatment discontinuations, and mortality were similar between groups, indicating that adding CD38-targeted therapy does not increase overall toxicity burden, supporting its feasibility in real-world settings.

Research Significance and Prospects

This study establishes Isa-KRd as one of the new standard treatment options for NDMM patients, particularly suitable for those pursuing deep molecular responses. From a research perspective, MRD negativity has been confirmed as a strong predictor of PFS and OS, enabling MRD-guided treatment strategies. Future studies could explore response-adapted therapies based on MRD status, such as shortening or eliminating chemotherapy in MRD-negative patients, while intensifying intervention in MRD-positive individuals. Additionally, these results support further development of carfilzomib-based quadruplet regimens as alternatives to traditional bortezomib combinations, especially when long-term therapy is needed to reduce neurotoxicity risks.

 

 

Conclusion

This study, through a high-quality phase 3 randomized trial, confirms that adding the CD38-targeted monoclonal antibody isatuximab to the KRd regimen significantly improves MRD negativity rates in transplant-eligible patients with newly diagnosed multiple myeloma, with particularly notable efficacy in high- and ultra-high-risk patients. These findings not only provide a new standard treatment option for clinical practice but also reinforce the role of MRD as a key efficacy endpoint in novel drug development. From bench to bedside, this study advances the concept of precision medicine—by enabling early and deep reduction of tumor burden, it may delay or even prevent disease progression. Especially for patients with t(11;14) or multiple high-risk abnormalities, Isa-KRd shows potential to overcome poor prognoses, suggesting that future treatment strategies should be personalized based on genetic risk stratification. Moreover, the favorable safety profile of this regimen enables long-term maintenance therapy and lays the foundation for combination with novel immunotherapies (e.g., CAR-T or bispecific antibodies). Overall, this study marks a critical step toward deeper responses and individualized management in multiple myeloma treatment and will serve as an important basis for future guideline updates.

 

Francesca Gay, Wilfried Roeloffzen, Meletios A Dimopoulos, Mario Boccadoro, and Annemiek Broijl. Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial. Nature Medicine.